Literature DB >> 11177661

Low-molecular weight heparins in coronary artery disease.

D Hunt1.   

Abstract

Recently published trials strongly support the use of low-molecular weight heparins in the treatment of unstable coronary syndromes. These agents provide an alternative to heparin that is at least as effective and safe, and does not require intravenous infusions or meticulous monitoring. Although comparative trials are not yet available, the available evidence allows for selection of specific agents in acute management of unstable angina. This review summarizes the current clinical data supporting the use of these agents.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11177661     DOI： 10.1007/s11883-001-0053-4

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN： 1523-3804            Impact factor:   5.113


  26 in total

1.  Combination enoxaparin-abciximab therapy during coronary intervention: the next standard of care?

Authors:  D A Tramuta; D J Kereiakes; E J Dippel; R Lengerich; T M Broderick; C W Abbottsmith; D D Whang; E M Roth; J F Schneider; W Howard; T M Shimshak
Journal:  J Invasive Cardiol       Date:  2000       Impact factor: 2.022

2.  Reduction of reinfarction and angina with use of low-molecular-weight heparin therapy after streptokinase (and heparin) in acute myocardial infarction.

Authors:  A Glick; R Kornowski; Y Michowich; B Koifman; A Roth; S Laniado; G Keren
Journal:  Am J Cardiol       Date:  1996-06-01       Impact factor: 2.778

Review 3.  Antithrombotic agents in coronary artery disease.

Authors:  J A Cairns; P Théroux; H D Lewis; M Ezekowitz; T W Meade; G C Sutton
Journal:  Chest       Date:  1998-11       Impact factor: 9.410

4.  Will the use of low-molecular-weight heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada?

Authors:  B J O'Brien; A Willan; G Blackhouse; R Goeree; M Cohen; S Goodman
Journal:  Am Heart J       Date:  2000-03       Impact factor: 4.749

5.  Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events [unstable angina or non-Q-wave myocardial infarction].

Authors:  D B Mark; P A Cowper; S D Berkowitz; L Davidson-Ray; E R DeLong; A G Turpie; R M Califf; B Weatherley; M Cohen
Journal:  Circulation       Date:  1998-05-05       Impact factor: 29.690

Review 6.  The emerging role of low-molecular-weight heparin and antiplatelet therapies in the cardiac catheterization laboratory.

Authors:  E Deutsch
Journal:  Am Heart J       Date:  1999-12       Impact factor: 4.749

Review 7.  Low-molecular-weight heparins for acute coronary syndromes.

Authors:  S A Spinler; J J Nawarskas
Journal:  Ann Pharmacother       Date:  1998-01       Impact factor: 3.154

8.  Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome).

Authors: 
Journal:  Eur Heart J       Date:  1999-11       Impact factor: 29.983

9.  Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease. Investigators.

Authors: 
Journal:  Lancet       Date:  1999-08-28       Impact factor: 79.321

10.  Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris.

Authors:  M M Rabah; J Premmereur; M Graham; J Fareed; D A Hoppensteadt; L L Grines; C L Grines
Journal:  Am J Cardiol       Date:  1999-12-15       Impact factor: 2.778
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.